Member Info for CHELSEA7

NOO

Buys 9k

Sells 251k

Room for a nice 250k?

You forgot to mention......permission, lol.

All sells.....................lets see.

At 7.12

At7.12

MMs still taking 215k+ at 7.12........good!!

7/7.50

MMs taking over 215k+ again at 7.12

Morning Ruck

Monday 43k
Tuesday 72k

Buys 30k
Sells 85k

Last Thursday we saw our buyer take 2 x 250k and 1 x 100k shares, Friday 2 x 100k after 350k shares sold into the market.

No buy showed yesterday, (could be delayed), but after taking 120k shares in the morning it rose to 180k shares at 7.12 and after 71k sells and a 1k buy four minutes from the close MMs upped it to over 215k+ at 7.12.

SO IMHO much the same today, MMs need shares to fill buyers order amd as I say last week we had to wait until Thursday/Friday to see 800ks worth of buys.

Suddenly taking 215k+ at 7.12

Taking 180k at 7.12.

Staggers me that they increase the bid to 7.1255 and hook a 50k sell!!

""The Real Lozan over on ADVFN. Short and sweet and to the point. AIMOO"""

LOL, so you believe we haven"t got a buyer too?? Short?? Maybe he is.

TF, I believe AIMOO is a variant on Honest Opinion

Interesting twist Dracula, and I am glad to hear you are switched on to ADVFN, hence the attacks on myself , Ratty and Inanaco.

You say......"".With the hope that a Major Pharma takes a early stage Interest. AIMOO""", seems like every post you put the emphasis on a Big Pharma deal now as it was on another BB.

I think at the moment that is unrealistic. Scancell have made it pretty clear they are going alone just now, so I am not expecting a sudden £1b deal at all. As I have said we have the potential here to build an income from licensing deals on all platforms, which will not only fund us through trials in the quest for data, but cover expenditure as we build a company with more staff than the current 24, and also add to the existing platforms.

We know of one deal that never materialised, perhaps it just fell well short of Scancells value, but I just wonder what Scancell could be valued at if we can grow to an income in the next couple of years of £30m-£50m and add data to the promise we believe in. I also feel Vulpes have a plan B in the event of needing funding in 2021.

Your emphasis on an emergency Pharma deal, if you like in a firesale is IMHO way off the mark here, and can I suggest you continue to DYOR rather than perhaps acting as an extension to Lozan and crew.

70k odd sells i see, if it stays this way expect IMHO a 100k min black trade at 7.25 to appear at the close or shortly after. ATB

Another tiny increase on the bid.

Up to 50k 7.1255

50k-180k 7.12

Not expecting fireworks personally, but we are creeping up slowly......................which is promising for a lifestyle company!!!

Oh well, off to the Post Office to pick up our £800, better take my Passport, Driving Licence, Bank Cards and fingerprints

Well there has been a muted response from PIs for a while now, who seem happy to hold and not so keen to buy more. I have been more interested in the words of Vulpes and their research scientist, whoever is building a holding, and I would imagine good news gets diminished as we have to read a 25 patient trial is too small, our treatments will shortly be obsolete, and the BOD are "inept".

Well a 100 patient trial would have been better, Hartlepool United should have signed Messi and Scancell can"t keep to timelines because the FDA and Ichor haven"t sorted out an issue which can"t be rocket science.

TBH I think an RNS showing patients are tolerating dosing well and registering immune responses will go down very well, and who knows the first RNS could be witheld to include that. Not expecting fireworks personally, but we are creeping up slowly

7/7.50

Will take 180k at 7.12......................all as close last night.

Really good news from AZ on a triple combination therapy for COPD (Chronic Obstructive Pulmonary Disease). They estimate there are 400 million sufferers world wide, and at present there are only two very ineffective treatments for it, for a disease that is progressive, leads to being housebound, and ultimately death. I actually believe there are far many more sufferers, in its early stages (1-4) it is difficult to recognise, and is often not until stage 2 that it is diagnosed.

https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/update-on-us-regulatory-review-of-pt010-in-copd/201910010700152872O/

It is not just in cancer that combination and triple combinations are producing better treatments.

So we enter Q4 2019, another year flying by and among my e-mails last night was one from Waitrose, to book my Xmas Delivery Slot, duly done for the 23rd December. Always been too late to secure a date before so pleased as punch to have done so.

Really good news from Sunday, my girlfriend picked all three numbers in the Lottery Pick 3, using our birthday dates and a mutual lucky number to win £800 after just a few months ago doing the same in the European Lottery to win £1500. Made our weekend, she has only been back from Hungary for a few months and is coming to the last few weeks of a contract as a live in carer for an elderly Hungarian lady here in London before moving in with me. So Scancell will be a good time to start seeing a rise as Chester suggests in the 14p-18p range for now at least.

I was saying last night how the MMs have slowly moved up from 6.80 to 7.12 to fill our buyers buys. Yesterday just another 14k were sold all day and I believe our buyer will have to move up from 7.25 and the MMs accordingly to see further buys. Friday we did see a seller and with that delayed 100k buy yesterday our buyer took those up pretty quickly late on. aSo perhaps until news we will see 7.20/7.50 before moving up again. Would appreciate somoone telling us how many we can buy on auto?? I doubt very much.

Thank you TF, they all are worth reading, I like Fierce Biotech articles they are short, to the point and easy to understand, so enjoy.

To a blue day here and maybe just a few PI buys will begin to make a difference too.

https://www.fiercebiotech.com/biotech/esmo-amgen-kras-colon-cancer-data-disappoints?mkt_tok=eyJpIjoiWkRZd1lUVXpNemRtWlRZeSIsInQiOiJoK3p3bDZoWVRSd1R2T042Q3BYR3ZqcHE2QkhDTWJVYzBOd2F4ZEw1TXlMT1pyY0RnaFVIaFNRR0o4SjJMM0lJK3NrRVNBQjNDWWIxM09NdmprYVZPa3Iyc1VSdXBzdmFCT1dnb3BFcUV3YzZSc3BTNW0rQnlScjhsV3BHbUtPQSJ9&mrkid=36433381

https://www.fiercepharma.com/pharma/esmo-merck-s-keytruda-posts-first-class-victory-pre-surgery-breast-cancer?mkt_tok=eyJpIjoiWkRZd1lUVXpNemRtWlRZeSIsInQiOiJoK3p3bDZoWVRSd1R2T042Q3BYR3ZqcHE2QkhDTWJVYzBOd2F4ZEw1TXlMT1pyY0RnaFVIaFNRR0o4SjJMM0lJK3NrRVNBQjNDWWIxM09NdmprYVZPa3Iyc1VSdXBzdmFCT1dnb3BFcUV3YzZSc3BTNW0rQnlScjhsV3BHbUtPQSJ9&mrkid=36433381

https://www.fiercebiotech.com/biotech/esmo-astellas-seattle-genetics-keytruda-combo-shrink-71-and-stamp-out-13-bladder-cancers?mkt_tok=eyJpIjoiWkRZd1lUVXpNemRtWlRZeSIsInQiOiJoK3p3bDZoWVRSd1R2T042Q3BYR3ZqcHE2QkhDTWJVYzBOd2F4ZEw1TXlMT1pyY0RnaFVIaFNRR0o4SjJMM0lJK3NrRVNBQjNDWWIxM09NdmprYVZPa3Iyc1VSdXBzdmFCT1dnb3BFcUV3YzZSc3BTNW0rQnlScjhsV3BHbUtPQSJ9&mrkid=36433381

https://www.fiercepharma.com/pharma/esmo-lilly-s-verzenio-looks-for-edge-gold-standard-data-tough-to-treat-patients?mkt_tok=eyJpIjoiWkRZd1lUVXpNemRtWlRZeSIsInQiOiJoK3p3bDZoWVRSd1R2T042Q3BYR3ZqcHE2QkhDTWJVYzBOd2F4ZEw1TXlMT1pyY0RnaFVIaFNRR0o4SjJMM0lJK3NrRVNBQjNDWWIxM09NdmprYVZPa3Iyc1VSdXBzdmFCT1dnb3BFcUV3YzZSc3BTNW0rQnlScjhsV3BHbUtPQSJ9&mrkid=36433381

Some very interesting articles